NYSE · CIK 0001757073
NVST Envista Holdings Corp
Insider trading from SEC Form 4. Last filing Aug 27, 2026. Close $23.00 on Oct 9, 2026, +21% from the 52-week low and -24% from the high.
In brief
Envista Holdings Corp (NVST) has 63 SEC Form 4 filings on file from 18 insiders, the latest filed on Aug 27, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 1 open-market sell worth $220k, net -$220k.
7 open-market trades have been scored at NVST. The newest: Mischa Reis (SVP, Strategy & Bus. Dev.) sold $220k of stock on Aug 20, 2026, filed Aug 24, 2026, scored 12 (weak), under a 10b5-1 plan. The largest of the 7 shown: Mischa Reis (SVP, Strategy & Bus. Dev.) sold $324k on Aug 25, 2025, scored 19 (weak), under a 10b5-1 plan. 4 insiders bought within 14 days of each other around Nov 16, 2023.
3 Form 144 notices of planned sales are on file, the latest filed Aug 20, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Envista Holdings Corp, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 12Weak | Mischa Reis SVP, Strategy & Bus. Dev. sell | $220k 8,000 shares | -23% | +42% from low-11% from high | |
| 4Weak | Mischa Reis SVP, Strategy & Bus. Dev. sell | $290k 9,675 shares | -27% | +104% from low0% from high | |
| 19Weak | Mischa Reis SVP, Strategy & Bus. Dev. sell | $324k 15,000 shares | -32% | - | |
| 55Moderate | Eric Conley SVP, Orthodontics buy | $50k 2,185 shares | +5% | +10% from low-46% from high | |
| 61Notable | Mark E Nance General Counsel buy | $109k 5,000 shares | +15% | +2% from low-49% from high | |
| 70Notable | Amir Aghdaei Chief Executive Officer buy | $215k 10,000 shares | +4% | +0% from low-50% from high | |
| 57Moderate | Stephen Keller Principal Financial Officer buy | $43k 2,000 shares | +18% | +0% from low-50% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 20, 2026 | Reis Mischa Officer | 8,000 0.01% of outstanding | $220k | Aug 20, 2026 | none |
| Feb 10, 2026 | Reis Mischa Officer | 9,675 0.01% of outstanding | $290k | Feb 10, 2026 | none |
| Aug 25, 2025 | Reis Mischa Officer | 15,000 0.01% of outstanding | $324k | Aug 25, 2025 | none |
Transactions
The newest 50 of 115 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | Eric D. Hammes Chief Financial Officer | FTax withholding Common Stock | -10,885 | $27.47 | $299k | 99,913 | Aug 27, 2026 |
| Aug 25, 2026 | Stefan Nilsson President, Nobel Biocare | FTax withholding Common Stock | -804 | $27.47 | $22k | 61,560 | Aug 27, 2026 |
| Aug 25, 2026 | Robert Befidi President, Diagnostics | FTax withholding Common Stock | -5,147 | $27.47 | $141k | 45,785 | Aug 27, 2026 |
| Aug 25, 2026 | Veronica Acurio President, Orthodontics | FTax withholding Common Stock | -7,710 | $27.47 | $212k | 48,806 | Aug 27, 2026 |
| Aug 20, 2026 | Mischa Reis SVP, Strategy & Bus. Dev. | SOpen-market sale Common Stock10b5-1 | -8,000 | $27.50 | $220k | 27,321 | Aug 24, 2026 |
| Aug 18, 2026 | Paul A Keel Chief Executive Officer | AGrant or award Common Stock | +179,730 | $0.00 | $0 | 551,304 | Aug 20, 2026 |
| Aug 18, 2026 | Eric D. Hammes Chief Financial Officer | AGrant or award Performance Share Unitderivative | +47,970 | $0.00 | $0 | 47,970 | Aug 20, 2026 |
| Aug 18, 2026 | Paul A Keel Chief Executive Officer | AGrant or award Performance Share Unitderivative | +159,900 | $0.00 | $0 | 159,900 | Aug 20, 2026 |
| May 25, 2026 | Paul A Keel Chief Executive Officer | FTax withholding Common Stock | -12,811 | $23.43 | $300k | 371,574 | May 27, 2026 |
| May 19, 2026 | Wendy Carruthers director | AGrant or award Common Stock | +9,330 | $0.00 | $0 | 59,940 | May 21, 2026 |
| May 19, 2026 | Christine A Tsingos director | AGrant or award Common Stock | +9,330 | $0.00 | $0 | 59,930 | May 21, 2026 |
| May 19, 2026 | Daniel Raskas director | AGrant or award Common Stock | +9,330 | $0.00 | $0 | 54,010 | May 21, 2026 |
| May 19, 2026 | Kieran Gallahue director | AGrant or award Common Stock | +9,330 | $0.00 | $0 | 54,010 | May 21, 2026 |
| May 19, 2026 | R Scott Huennekens director | AGrant or award Common Stock | +12,585 | $0.00 | $0 | 82,105 | May 21, 2026 |
| May 19, 2026 | James Andrew Pierce director | AGrant or award Common Stock | +9,330 | $0.00 | $0 | 18,485 | May 21, 2026 |
| May 19, 2026 | Vivek Jain director | AGrant or award Common Stock | +9,330 | $0.00 | $0 | 52,945 | May 21, 2026 |
| Feb 25, 2026 | Mark E Nance General Counsel | FTax withholding Common Stock | -3,368 | $29.59 | $100k | 68,577 | Feb 27, 2026 |
| Feb 25, 2026 | Veronica Acurio President, Orthodontics | FTax withholding Common Stock | -1,412 | $29.59 | $42k | 48,911 | Feb 27, 2026 |
| Feb 25, 2026 | Mischa Reis SVP, Strategy & Bus. Dev. | FTax withholding Common Stock | -2,976 | $29.59 | $88k | 29,406 | Feb 27, 2026 |
| Feb 25, 2026 | Faez C Kaabi Chief Accounting Officer | FTax withholding Common Stock | -4,964 | $29.59 | $147k | 45,032 | Feb 27, 2026 |
| Feb 25, 2026 | Stefan Nilsson President, Nobel Biocare | FTax withholding Common Stock | -182 | $29.59 | $5,385 | 54,759 | Feb 27, 2026 |
| Feb 25, 2026 | Robert Befidi President, Diagnostics | FTax withholding Common Stock | -2,177 | $29.59 | $64k | 43,327 | Feb 27, 2026 |
| Feb 25, 2026 | Eric D. Hammes Chief Financial Officer | FTax withholding Common Stock | -2,045 | $29.59 | $61k | 94,743 | Feb 27, 2026 |
| Feb 25, 2026 | Paul A Keel Chief Executive Officer | FTax withholding Common Stock | -11,840 | $29.59 | $350k | 335,715 | Feb 27, 2026 |
| Feb 25, 2026 | Mark E Nance General Counsel | AGrant or award Common Stock | +12,675 | $0.00 | $0 | 81,252 | Feb 27, 2026 |
| Feb 25, 2026 | Veronica Acurio President, Orthodontics | AGrant or award Common Stock | +7,605 | $0.00 | $0 | 56,516 | Feb 27, 2026 |
| Feb 25, 2026 | Mischa Reis SVP, Strategy & Bus. Dev. | AGrant or award Common Stock | +5,915 | $0.00 | $0 | 35,321 | Feb 27, 2026 |
| Feb 25, 2026 | Robert Befidi President, Diagnostics | AGrant or award Common Stock | +7,605 | $0.00 | $0 | 50,932 | Feb 27, 2026 |
| Feb 25, 2026 | Faez C Kaabi Chief Accounting Officer | AGrant or award Common Stock | +13,520 | $0.00 | $0 | 58,552 | Feb 27, 2026 |
| Feb 25, 2026 | Stefan Nilsson President, Nobel Biocare | AGrant or award Common Stock | +7,605 | $0.00 | $0 | 62,364 | Feb 27, 2026 |
| Feb 25, 2026 | Eric D. Hammes Chief Financial Officer | AGrant or award Common Stock | +16,055 | $0.00 | $0 | 110,798 | Feb 27, 2026 |
| Feb 25, 2026 | Paul A Keel Chief Executive Officer | AGrant or award Common Stock | +48,670 | $0.00 | $0 | 384,385 | Feb 27, 2026 |
| Feb 25, 2026 | Mark E Nance General Counsel | AGrant or award Performance Share Unitderivative | +23,070 | $0.00 | $0 | 23,070 | Feb 27, 2026 |
| Feb 25, 2026 | Veronica Acurio President, Orthodontics | AGrant or award Performance Share Unitderivative | +13,845 | $0.00 | $0 | 13,845 | Feb 27, 2026 |
| Feb 25, 2026 | Mischa Reis SVP, Strategy & Bus. Dev. | AGrant or award Performance Share Unitderivative | +10,770 | $0.00 | $0 | 10,770 | Feb 27, 2026 |
| Feb 25, 2026 | Stefan Nilsson President, Nobel Biocare | AGrant or award Performance Share Unitderivative | +13,845 | $0.00 | $0 | 13,845 | Feb 27, 2026 |
| Feb 25, 2026 | Robert Befidi President, Diagnostics | AGrant or award Performance Share Unitderivative | +13,845 | $0.00 | $0 | 13,845 | Feb 27, 2026 |
| Feb 25, 2026 | Eric D. Hammes Chief Financial Officer | AGrant or award Performance Share Unitderivative | +29,225 | $0.00 | $0 | 29,225 | Feb 27, 2026 |
| Feb 25, 2026 | Paul A Keel Chief Executive Officer | AGrant or award Performance Share Unitderivative | +132,885 | $0.00 | $0 | 132,885 | Feb 27, 2026 |
| Feb 25, 2026 | Paul A Keel Chief Executive Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +115,320 | $0.00 | $0 | 115,320 | Feb 27, 2026 |
| Feb 25, 2026 | Mark E Nance General Counsel | AGrant or award Employee Stock Option (Right to Buy)derivative | +30,040 | $0.00 | $0 | 30,040 | Feb 27, 2026 |
| Feb 25, 2026 | Veronica Acurio President, Orthodontics | AGrant or award Employee Stock Option (Right to Buy)derivative | +18,020 | $0.00 | $0 | 18,020 | Feb 27, 2026 |
| Feb 25, 2026 | Mischa Reis SVP, Strategy & Bus. Dev. | AGrant or award Employee Stock Option (Right to Buy)derivative | +14,020 | $0.00 | $0 | 14,020 | Feb 27, 2026 |
| Feb 25, 2026 | Stefan Nilsson President, Nobel Biocare | AGrant or award Employee Stock Option (Right to Buy)derivative | +18,020 | $0.00 | $0 | 18,020 | Feb 27, 2026 |
| Feb 25, 2026 | Robert Befidi President, Diagnostics | AGrant or award Employee Stock Option (Right to Buy)derivative | +18,020 | $0.00 | $0 | 18,020 | Feb 27, 2026 |
| Feb 25, 2026 | Eric D. Hammes Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +38,040 | $0.00 | $0 | 38,040 | Feb 27, 2026 |
| Feb 10, 2026 | Mischa Reis SVP, Strategy & Bus. Dev. | MOption exercise Common Stock10b5-1 | +4,041 | $19.04 | $77k | 36,423 | Feb 11, 2026 |
| Feb 10, 2026 | Mischa Reis SVP, Strategy & Bus. Dev. | SOpen-market sale Common Stock10b5-1 | -4,041 | $30.00 | $121k | 32,382 | Feb 11, 2026 |
| Feb 10, 2026 | Mischa Reis SVP, Strategy & Bus. Dev. | MOption exercise Common Stock10b5-1 | +5,634 | $15.97 | $90k | 38,016 | Feb 11, 2026 |
| Feb 10, 2026 | Mischa Reis SVP, Strategy & Bus. Dev. | SOpen-market sale Common Stock10b5-1 | -5,634 | $30.00 | $169k | 32,382 | Feb 11, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Veronica AcurioPresident, Orthodontics
- Amir AghdaeiChief Executive Officer
- Robert BefidiPresident, Diagnostics
- Wendy Carruthersofficer, director
- Eric ConleySVP, Orthodontics
- Kieran Gallahuedirector
- Eric D. HammesChief Financial Officer
- R Scott Huennekensdirector
- Vivek Jainceo, chair, officer, director
- Faez C KaabiChief Accounting Officer
- Paul A KeelChief Executive Officer
- Stephen KellerPrincipal Financial Officer
- Mark E NanceGeneral Counsel
- Stefan NilssonPresident, Nobel Biocare
- James Andrew Piercepresident, officer, director
- Daniel Raskasofficer, director
- Mischa ReisSVP, Strategy & Bus. Dev.
- Christine A Tsingosdirector
Questions about NVST
Answered from the filings on this page, as of the latest one.
Are insiders buying NVST?
As of Aug 27, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 1 open-market sell worth $220k by 1 insider at Envista Holdings Corp in the last 90 days, net -$220k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade NVST on the open market?
Mischa Reis (SVP, Strategy & Bus. Dev.) sold $220k of NVST on Aug 20, 2026 and filed the Form 4 on Aug 24, 2026. InsiderTell scored 12 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at Envista Holdings Corp?
18 people have filed a Form 4 at Envista Holdings Corp, among them Veronica Acurio (President, Orthodontics), Amir Aghdaei (Chief Executive Officer), Robert Befidi (President, Diagnostics). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.